Brokerages predict that Adamis Pharmaceuticals Corp (NASDAQ:ADMP) will announce sales of $5.25 million for the current quarter, according to Zacks. Two analysts have made estimates for Adamis Pharmaceuticals’ earnings. The lowest sales estimate is $5.20 million and the highest is $5.29 million. Adamis Pharmaceuticals posted sales of $3.92 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 33.9%. The company is expected to issue its next quarterly earnings report on Friday, August 9th.
On average, analysts expect that Adamis Pharmaceuticals will report full year sales of $22.64 million for the current financial year, with estimates ranging from $21.20 million to $24.08 million. For the next financial year, analysts expect that the company will post sales of $26.70 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Adamis Pharmaceuticals.
Adamis Pharmaceuticals (NASDAQ:ADMP) last released its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.04). Adamis Pharmaceuticals had a negative return on equity of 94.94% and a negative net margin of 239.53%. The firm had revenue of $4.91 million for the quarter, compared to analyst estimates of $5.95 million.
Several equities research analysts recently issued reports on ADMP shares. Maxim Group set a $10.00 price objective on shares of Adamis Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, March 19th. Raymond James set a $4.00 price objective on shares of Adamis Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, May 10th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $5.25.
In other Adamis Pharmaceuticals news, VP Karen K. Daniels sold 13,911 shares of Adamis Pharmaceuticals stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $2.30, for a total transaction of $31,995.30. Following the completion of the sale, the vice president now directly owns 179,944 shares in the company, valued at $413,871.20. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Dennis J. Phd Carlo sold 13,292 shares of Adamis Pharmaceuticals stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $2.27, for a total transaction of $30,172.84. Following the sale, the chief executive officer now owns 42,353 shares of the company’s stock, valued at $96,141.31. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,329 shares of company stock valued at $121,847. Company insiders own 10.20% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC bought a new stake in shares of Adamis Pharmaceuticals in the fourth quarter worth about $31,000. Jefferies Group LLC acquired a new position in Adamis Pharmaceuticals during the first quarter valued at approximately $34,000. Charles Schwab Investment Management Inc. acquired a new position in Adamis Pharmaceuticals during the first quarter valued at approximately $35,000. Cambridge Investment Research Advisors Inc. acquired a new position in Adamis Pharmaceuticals during the fourth quarter valued at approximately $36,000. Finally, Oppenheimer & Co. Inc. acquired a new position in Adamis Pharmaceuticals during the fourth quarter valued at approximately $38,000. Institutional investors and hedge funds own 17.42% of the company’s stock.
Adamis Pharmaceuticals stock traded down $0.06 during midday trading on Friday, hitting $1.89. 160,870 shares of the stock were exchanged, compared to its average volume of 382,162. Adamis Pharmaceuticals has a fifty-two week low of $1.83 and a fifty-two week high of $5.10. The stock has a market cap of $92.22 million, a P/E ratio of -1.89 and a beta of 1.35. The company has a current ratio of 1.53, a quick ratio of 1.95 and a debt-to-equity ratio of 0.03.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
See Also: Reverse Stock Split
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.